Clinical trials: Covid19- Coronavirus- Sars-cov-2
SARS CoV 2 Infection
A Phase IV Vaccine Study Under the National Cohort Study of Effectiveness and Safety of SARS-CoV-2 (COVID-19) Vaccines.
A phase IV study to assess if the SARS-CoV-2 vaccine from Johnson \& Johnson/Janssen (J\&J) results in change in number and activation of platelets and anti-PF4 Level.
- Trial name
- NCT06360744
- Testing
- Johnson & Johnson
- Where
- 5 sites in Denmark
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Jens D Lundgren, MD
Covid19
Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents
This Phase 1 trial is an open-label trial to evaluate the safety, reactogenicity and immunogenicity of two dosages (10^6 PFU and 10^7 PFU) of intranasal CVXGA1 administered as a single dose in healthy adults age 18-55 years and…
- Trial name
- CVXGA1-001 (NCT04954287)
- Testing
- CVXGA1 low dose, CVXGA1 high dose
- Where
- 4 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- CyanVac LLC
COVID-19, Long-COVID
Symptom-based Rehabilitation Compared to Usual Care in Post-COVID - a Randomized Controlled Trial
Inpatient, multimodal rehabilitation represents one of the most important interventions in the disease management of post/long COVID.
- Trial name
- RELOAD (NCT05172206)
- Testing
- symptom-focused rehabilitation, usual care
- Where
- 8 sites in Germany
- Volunteers
- 132 people
- Sponsor
- Schön Klinik Berchtesgadener Land
Anogenital Herpes, COVID-19
Viral Infections in Healthy and Immunocompromised Hosts
Background: Viral infections are an important cause of illness and death in hospitalized patients as well as outpatients. New strains of viruses may appear and infect both healthy people and those with weak immune systems.
- Conditions
- Anogenital Herpes, COVID-19, Herpes Labialis
- Trial name
- NCT01306084
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV Infection, Respiratory Viral Infection
COVID-19 Testing Sample Acquisition Throughput and Efficiency
This QI project seeks to evaluate the relative test sample acquisition throughput, personal protective equipment utilization, and relative operational costs of provider-administered COVID-19 (SARS-CoV-2) nasal samples with and…
- Conditions
- SARS-CoV Infection, Respiratory Viral Infection, Personal Protective Equipment, Covid19
- Trial name
- HexapodBooth (NCT04532411)
- Testing
- Personal Protective Testing Booth
- Where
- United States
- Volunteers
- 28,948 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Adjustment Reaction With Physical Symptoms
Use of Homeopathy in Patients Suffering From Long COVID-19
In some patients, coronavirus (COVID-19) can cause symptoms that last weeks or even months after the infection has gone. The aim of this study was to describe the effect of adjunctive individualized homeopathic treatment…
- Trial name
- LONGCOVIHOM (NCT06002230)
- Testing
- Homeopathic medicines
- Where
- Austria
- Volunteers
- 15 people
- Sponsor
- Michael Frass
COVID19
Phase I/II Safety, Dose Finding & Antiviral Activity of RD-X19 in Mild/Moderate Outpatient COVID-19
This randomized, Phase I/II feasibility study will evaluate the safety and efficacy of the RD-X19 device in SARS-CoV-2 infected individuals with uncomplicated COVID-19.
- Trial name
- NCT04662671
- Testing
- RD-X19
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- EmitBio Inc.
Coronavirus Infection, Coronavirus
Convalescent Plasma for Patients With COVID-19
Pilot study of tolerability and efficacy of transfusion of 200mL of convalescent plasma in patients with COVID-19 respiratory disease.
- Conditions
- Coronavirus Infection, Coronavirus, COVID
- Trial name
- NCT04385199
- Testing
- Convalescent plasma
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Henry Ford Health System
SARS-CoV-2
Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
The goal of this study is to confirm the onset status of hypersensitivity reactions including shock and anaphylaxis observed after vaccination with this drug in persons with underlying diseases who are considered to have a high…
- Trial name
- NCT05894499
- Where
- Japan
- Volunteers
- 13,309 people
- Sponsor
- ModernaTX, Inc.
Long COVID
A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID
The IMPACT Long Covid Treatment clinical study (IMPACT-LC) is testing two repurposed and previously approved drugs, Maraviroc and Atorvastatin, for the treatment of non-hospitalized subjects with Long COVID.
- Trial name
- IMPACT-LC (NCT06974084)
- Testing
- Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg
- Where
- United States
- Volunteers
- 252 people
- Sponsor
- HealthBio, Inc.
Cerebrovascular Accident, Chronic Obstructive Pulmonary Disease
Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)
This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection.
- Conditions
- Cerebrovascular Accident, Chronic Obstructive Pulmonary Disease, Chronic Renal Failure, Coronary Artery Disease
- Trial name
- NCT04361552
- Testing
- Best Practice, Tocilizumab
- Where
- United States
- Sponsor
- Emory University
COVID-19, COVID-19 Pandemic
Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis
The purpose of this retrospective study is to evaluate the effectiveness of CPM nasal spray as part of the treatment of COVID-19 and its impact on clinical symptoms. Two cohort groups will be compared (CPM vs. standard care).
- Conditions
- COVID-19, COVID-19 Pandemic, COVID-19 Respiratory Infection, SARS CoV 2 Infection
- Trial name
- ACCROS-R (NCT05520944)
- Testing
- ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray
- Where
- Dominican Republic
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Dr. Ferrer BioPharma
SARS-CoV-2
Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGE
The main objective of the surveillance is to evaluate the incidence of the adverse events (AEs), and other safety-related information in South-Korean population.
- Trial name
- NCT06333704
- Testing
- SPIKEVAX Bivalent BA.1, SPIKEVAX Bivalent BA.4/5, SPIKEVAX XBB.1.5
- Where
- 26 sites in South Korea
- Volunteers
- 4,207 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19
Povidone-Iodine Oral Rinse Study
This study is a two-arm, randomized, 2-phase study. Phase I will be double blinded clinical trial of the safety and efficacy of an antiseptic mouthwash solution on reducing SARS-CoV-2 load in COVID 19+ adult individuals.
- Trial name
- NCT05239598
- Testing
- Mouth rinse
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Pennsylvania
Biochemical Markers ,NGAL,Cystatin c, Acute Kidneyinjury, Covid 19
Role of NGAL and Cystatin C in Prediction of Acute Kidney Injury Covid-19 Infection
Recent different biomarkers of acute kidney injury (AKI) have been manufactured by pharmaceutical industry. Studies proved that Neutrophil gelatinase-associated lipocalin (NGAL) and cystatin c are effective predictive biomarkers…
- Trial name
- NCT04603664
- Testing
- serum NGAL and cystatin c
- Where
- 2 sites in Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
COVID, Covid-19
A Study of ResCure™ to Treat COVID-19 Infection
This is a Phase I open-label interventional study which will test the efficacy of ResCure™ in the treatment of patients with COVID-19 infection.
- Conditions
- COVID, Covid-19, Corona Virus Infection, Sars-CoV2
- Trial name
- NCT04395716
- Testing
- ResCure™
- Where
- United States
- Sponsor
- ProgenaBiome
COVID-19
Impact of New Variants and Vaccines on the Course of COVID-19
Novel coronavirus disease (COVID-19), caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, was first reported in December 2019 in Wuhan, China.
- Trial name
- COVID-19 (NCT05384886)
- Testing
- Polymerase chain reaction
- Where
- Turkey (Türkiye)
- Volunteers
- 15,967 people
- Sponsor
- Izmir Katip Celebi University
Covid19, SARS-CoV Infection
COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)
1. The purpose of this trial is to conduct a 2x3 factorial randomized trials, which efficiently allows the parallel conduct of three randomized trials to understand whether metformin, ivermectin, or fluvoxamine, is superior to…
- Trial name
- NCT04510194
- Testing
- Metformin, Fluvoxamine, Ivermectin
- Where
- 7 sites in United States
- Volunteers
- 1,323 people
- Sponsor
- University of Minnesota
Advanced Care Planning, Shared Decision Making
Advance Care Planning: Communicating With Outpatients for Vital Informed Decision
This Pre-Post, open-cohort design, pragmatic trial with 150 clinicians and will evaluate the effectiveness of the use of telehealth Advanced Care Planning (ACP) Program by comparing ACP documentation among 13,000 patients over 65
- Conditions
- Advanced Care Planning, Shared Decision Making, Video Decision Aids, Communication Skills
- Trial name
- ACP-COVID (NCT04660422)
- Testing
- VitalTalk communication skills training, ACP Decisions Video Program, Intervention training:
- Where
- United States
- Volunteers
- 42,019 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Covid19, Sars-CoV-2 Infection
Performance Study of SONA Saliva C-19 Rapid Test
The Sona Saliva C-19 Rapid Test is a bioassay intended for rapid point-of-care detection of the SARS-CoV-2 virus. Performance of the Sona Saliva C-19 Rapid Test assay will be assessed by comparison to a RT-PCR reference method
- Conditions
- Covid19, Sars-CoV-2 Infection, Corona Virus Infection
- Trial name
- NCT04877002
- Testing
- Sona Saliva C-19 Rapid Test
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Sona Nanotech Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.